The trial of a new drug, bexobrutideg, shows promising results for chronic lymphocytic leukemia patients previously treated ...

Researchers conducted the IMPROVE trial to evaluate whether a 3-week pause in BTK inhibitor use would improve immunity after COVID-19 booster vaccination without negatively affecting disease control ...

Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.

Despite advances, the roles of genetics and microenvironment in CLL are not fully understood, and curative treatments may ...

Research presented at ASCO 2025 highlighted potential treatments for patients with newly diagnosed and relapsed or refractory ...

A University of Brighton graduate has transformed his personal cancer journey into a striking and thought-provoking art ...

DelveInsight’s, “Chronic Lymphocytic Leukemia Pipeline Insight 2025” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia (CLL) pipeline ...

Personalized drug treatments have outperformed chemotherapy for leukemia patients in a trial led by Leeds researchers. Newly ...

The VERONA trial evaluated the safety and efficacy of venetoclax with azacitidine in treatment-naïve adults with higher-risk MDS.

Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

GEO-CM04S1 Demonstrates Superior T Cell Responses Compared to mRNA Vaccine in Phase 2 Trial Among Immunocompromised Patients ...